secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011474
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE
--------------------------------------------------------------------------------

- Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.
- PIPE financing closed July 2024 with initial $30.3M; up to $122.7M total tied to warrant milestones from healthcare specialist investors.
- Cash and equivalents $1.0M at June 30, 2024 (down from $12.6M at Dec 31, 2023); subsequent PIPE strengthens balance sheet.
- Net loss $2.6M for Q2 2024 vs $2.3M in Q2 2023; R&D expenses $1.6M (up $0.6M YoY) driven by PMN310 clinical costs.
- Company expects to report topline results from all five cohorts in H2 2024 and initiate a Phase 1b trial in 100 AD patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/0001558370-24-011474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/pmn-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer